ES2606545T3 - Método de almacenar una vacuna que contiene un adyuvante de aluminio - Google Patents

Método de almacenar una vacuna que contiene un adyuvante de aluminio Download PDF

Info

Publication number
ES2606545T3
ES2606545T3 ES11772945.9T ES11772945T ES2606545T3 ES 2606545 T3 ES2606545 T3 ES 2606545T3 ES 11772945 T ES11772945 T ES 11772945T ES 2606545 T3 ES2606545 T3 ES 2606545T3
Authority
ES
Spain
Prior art keywords
syringes
desorption
months
hbsag
storing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11772945.9T
Other languages
English (en)
Inventor
Isabelle Chacornac
Nabila Ikhelef-Gribi
Frédéric RONZON
Julien Tirefort
Sandrine Lentsch Graf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44059027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2606545(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Application granted granted Critical
Publication of ES2606545T3 publication Critical patent/ES2606545T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/005—Closures provided with linings or internal coatings so as to avoid contact of the closure with the contents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00—Closing containers or receptacles after filling
    • B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
    • B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
    • B65B7/2821—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers applying plugs or threadless stoppers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D39/00—Closures arranged within necks or pouring openings or in discharge apertures, e.g. stoppers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/002—Closures to be pierced by an extracting-device for the contents and fixed on the container by separate retaining means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2539/00—Details relating to closures arranged within necks or pouring openings or in discharge apertures, e.g. stoppers
    • B65D2539/001—Details of closures arranged within necks or pouring opening or in discharge apertures, e.g. stoppers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mechanical Engineering (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Un recipiente para almacenar y/o administrar una composición de vacuna, en donde el recipiente contiene una composición de vacuna que comprende un antígeno de la hepatitis B adsorbido sobre un adyuvante de oxihidróxido de aluminio y está cerrado por un dispositivo que actúa como un tapón, en donde la superficie del dispositivo contactable con la composición está revestida con un polímero fluorado.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
5
10
15
20
25
30
35
40
A T (tiempo) = 0, el nivel de adsorción de HbsAg era idéntico en las tres categorías (se adsorbió el 98% del total de HBsAg). A T = 2 meses se observó una desorción en todas las categorías, pero el porcentaje de desorción difería dependiendo de la categoría. El porcentaje de desorción más alto se encontró en la categoría (1) (a T = 1 y 2 meses, se adsorbió 55 y 50% del HBsAg total, respectivamente), mientras que el porcentaje más bajo se encontró en la categoría (3) (A T = 1 y 2 meses, se adsorbieron 72 y 69% del total de HBsAg, respectivamente).
B -Una gran parte de la composición de vacuna descrita en A -se distribuyó en dos categorías de una dosis única de jeringas de 1 mL, cuyas características eran las siguientes:
(1)
jeringas de vidrio siliconizadas estándares (silicona libre); y
(2)
jeringas no siliconizadas.
La mayor parte se distribuyó en dosis únicas de 0,5 mL, conteniendo cada una de las dosis 10 µg de HBsAg, 30 Lf de Dt, 10 Lf de Tt, 25 µg de Pt, 25 µg de FHA, 40 DU (Unidad de antígeno D) de IPV1, 8 DU de IPV2, 32 DU de IPV3, 12 µg de PRP (en forma conjugada PRP-Tt), 0,6 mg de Al, 55 mM de iones fosfato, 20 mM de iones carbonato y tampón Tris sacarosa, 2,5 mM, 2,125%, a pH 6,8-7,2.
Todas las jeringas de las dos categorías fueron almacenadas horizontalmente a 25°C durante dos meses (envejecimiento acelerado). La desorción de HBsAg se midió en cada una de las dos categorías a T = 0 (justo después de cargar las jeringas) y luego después de dos meses, tal como se describe en A -arriba.
A T (tiempo) = 0, el nivel de adsorción de HbsAg era idéntico en las dos categorías (se adsorbió el 98% del total de HBsAg). A T = 2 meses se observó una desorción en todas las categorías, pero el porcentaje de desorción difería dependiendo de la categoría. El porcentaje de desorción más alto se encontró en la categoría (1) (a T = 1 y 2 meses, se adsorbió 69 y 68% del HBsAg total, respectivamente), mientras que el porcentaje de desorción más bajo se encontró en la categoría (2) (A T = 1 y 2 meses, se adsorbió 73% del total de HBsAg). Esto indica claramente que la adsorción del antígeno sobre un adyuvante de aluminio es sensible a la silicona libre.
C -Una gran parte de la composición de la vacuna descrita en A -se distribuyó en tres tipos de jeringas de dosis única de 1 mL, cuyas características eran las siguientes:
(1)
jeringas de vidrio poco siliconizadas (50-100 µg de silicona libre/jeringa);
(2)
jeringas de vidrio altamente siliconizadas estándares ((jeringa RTF Luercone™ de Gerresheimer): 800 µg a 1 mg de silicona libre/jeringa); y
(3)
jeringas que tenían la superficie interior recubierta con silicona polimerizada (50-100 µg/jeringa).
Jeringas de la categoría (1) son operativas solamente si el émbolo utilizado para la inyección también está siliconizado, porque la cantidad de silicona que recubre la superficie interior de la jeringa es demasiado baja para permitir el deslizamiento por sí misma.
Todas las jeringas (tipos 1 a 3) se cerraron con el mismo tipo de tapón no siliconizado.
La vacuna a granel se distribuyó en dosis únicas de 0,5 mL, siendo cada una de las dosis como se describe en A y
B.
Todas las jeringas de los tres tipos fueron almacenadas verticalmente a 25°C durante dos meses (envejecimiento acelerado). La desorción de HBsAg se midió en cada uno de los tres tipos a T = 0 (justo después de llenar las jeringas) y luego después de dos meses, tal como se describe en A -arriba.
A T (tiempo) = 0, el nivel de adsorción de HbsAg era idéntico en los tres tipos (se adsorbió el 94% del total de HBsAg). A T = 2 meses, se observó una desorción en todas las jeringas, pero el porcentaje de desorción difería dependiendo del tipo. El porcentaje de desorción más alto se encontró en el tipo (2) (a T = 1 y 2 meses, se adsorbió 60 y 58% del HBsAg total, respectivamente), mientras que el porcentaje de desorción se encontró similar en los tipos
8
imagen7

Claims (1)

  1. imagen1
ES11772945.9T 2010-10-18 2011-10-17 Método de almacenar una vacuna que contiene un adyuvante de aluminio Active ES2606545T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1058464A FR2966044B1 (fr) 2010-10-18 2010-10-18 Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
FR1058464 2010-10-18
US201161454248P 2011-03-18 2011-03-18
US201161454248P 2011-03-18
PCT/EP2011/068090 WO2012052394A1 (en) 2010-10-18 2011-10-17 Method of storing a vaccine containing an aluminum adjuvant

Publications (1)

Publication Number Publication Date
ES2606545T3 true ES2606545T3 (es) 2017-03-24

Family

ID=44059027

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11772945.9T Active ES2606545T3 (es) 2010-10-18 2011-10-17 Método de almacenar una vacuna que contiene un adyuvante de aluminio

Country Status (33)

Country Link
US (2) US9066895B2 (es)
EP (1) EP2629792B1 (es)
JP (2) JP5890837B2 (es)
KR (1) KR101875828B1 (es)
CN (2) CN103140239A (es)
AP (1) AP2013006876A0 (es)
AR (2) AR084491A1 (es)
AU (1) AU2011317649B2 (es)
BR (1) BR112013009524B1 (es)
CA (1) CA2811075C (es)
CR (1) CR20130223A (es)
CY (1) CY1118557T1 (es)
DK (1) DK2629792T3 (es)
EA (1) EA026876B1 (es)
ES (1) ES2606545T3 (es)
FR (1) FR2966044B1 (es)
GE (1) GEP20156238B (es)
GT (1) GT201300094A (es)
HR (1) HRP20161637T1 (es)
HU (1) HUE031210T2 (es)
IL (1) IL225431A (es)
LT (1) LT2629792T (es)
ME (1) ME02614B (es)
MX (1) MX342345B (es)
NZ (1) NZ609973A (es)
PE (1) PE20140850A1 (es)
PL (1) PL2629792T3 (es)
PT (1) PT2629792T (es)
RS (1) RS55520B1 (es)
SI (1) SI2629792T1 (es)
UA (1) UA113049C2 (es)
WO (1) WO2012052394A1 (es)
ZA (1) ZA201303164B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
EP3858405B1 (en) 2012-06-01 2023-04-05 Novartis AG Syringe
EP2861526A4 (en) * 2012-06-18 2015-12-16 Innova Dynamics Inc AGGLOMERATE REDUCTION IN A NANODRAHUSUSPENSION STORED IN A CONTAINER
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
CN103471902A (zh) * 2013-09-22 2013-12-25 北京智飞绿竹生物制药有限公司 一种解吸附方法及其应用
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US10406290B2 (en) * 2015-02-03 2019-09-10 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled plastic syringe
CA3007276C (en) 2015-12-03 2021-12-28 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitor to treat macular degeneration in a patient population
CA3047329A1 (en) 2016-12-28 2018-07-05 Sanbio, Inc. Cell delivery system and methods of operation thereof
EP3769082A4 (en) * 2018-03-20 2021-12-15 Sanofi Pasteur Limited METHODS FOR DETERMINING THE CONCENTRATION OF ADJUVANT PROTEIN AND THE PERCENTAGE OF ADSORPTION USING INTRINSIC FLUORESCENCE
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
DE102018124115A1 (de) * 2018-09-28 2020-04-02 Schott Schweiz Ag Primärpackmittel für pharmazeutische Substanzen
CA3157652A1 (en) * 2019-10-16 2021-04-22 Janssen Vaccines & Prevention B.V. Vaccine product
CN113274492B (zh) * 2021-05-21 2022-06-17 大连理工大学 一种基于羟基氧化铝纳米羧基改性的复合疫苗佐剂的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2545540B2 (ja) * 1987-05-29 1996-10-23 株式会社 大協精工 両面ラミネ−トゴム栓
PT835663E (pt) * 1992-05-23 2010-01-04 Glaxosmithkline Biolog Sa Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
EP1175912A1 (en) * 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US6200627B1 (en) * 1998-03-17 2001-03-13 Becton, Dickinson And Company Low silicone glass prefillable syringe
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
KR101092043B1 (ko) * 2002-04-22 2011-12-12 바이오니취 라이프 사이언시즈 인코포레이티드 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
JP2004298220A (ja) * 2003-03-28 2004-10-28 Terumo Corp プレフィルドシリンジ
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
GB0610140D0 (en) * 2006-05-22 2006-06-28 Insense Ltd Protein stability
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
GB0609612D0 (en) 2006-05-15 2006-06-21 Glaxosmithkline Biolog Sa Detection method and kit
WO2008076819A2 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
BRPI0909820A2 (pt) * 2008-03-05 2015-08-11 Sanofi Pasteur Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
WO2010064667A1 (ja) * 2008-12-03 2010-06-10 電気化学工業株式会社 シリンジ

Also Published As

Publication number Publication date
EA201390585A1 (ru) 2014-03-31
EA026876B1 (ru) 2017-05-31
AR120025A2 (es) 2022-01-26
JP5890837B2 (ja) 2016-03-22
ZA201303164B (en) 2014-06-25
US20120091026A1 (en) 2012-04-19
IL225431A0 (en) 2013-06-27
EP2629792B1 (en) 2016-11-23
FR2966044B1 (fr) 2012-11-02
KR101875828B1 (ko) 2018-07-06
JP2016093534A (ja) 2016-05-26
CA2811075A1 (en) 2012-04-26
CN107753944A (zh) 2018-03-06
JP2013541380A (ja) 2013-11-14
PL2629792T3 (pl) 2017-07-31
CY1118557T1 (el) 2017-07-12
ME02614B (me) 2017-06-20
UA113049C2 (xx) 2016-12-12
LT2629792T (lt) 2017-01-10
GT201300094A (es) 2014-11-06
NZ609973A (en) 2014-09-26
AU2011317649B2 (en) 2014-09-18
FR2966044A1 (fr) 2012-04-20
PE20140850A1 (es) 2014-08-01
EP2629792A1 (en) 2013-08-28
SI2629792T1 (sl) 2017-04-26
AR084491A1 (es) 2013-05-22
CR20130223A (es) 2013-06-27
IL225431A (en) 2017-07-31
US9066895B2 (en) 2015-06-30
BR112013009524B1 (pt) 2021-01-26
AU2011317649A1 (en) 2013-03-28
JP6577369B2 (ja) 2019-09-18
DK2629792T3 (da) 2017-01-02
PT2629792T (pt) 2016-12-16
CA2811075C (en) 2020-01-14
BR112013009524A2 (pt) 2018-12-11
WO2012052394A1 (en) 2012-04-26
MX342345B (es) 2016-09-26
HUE031210T2 (en) 2017-07-28
RS55520B1 (sr) 2017-05-31
GEP20156238B (en) 2015-01-26
KR20130126615A (ko) 2013-11-20
CN103140239A (zh) 2013-06-05
US20150259111A1 (en) 2015-09-17
AP2013006876A0 (en) 2013-05-31
US9938055B2 (en) 2018-04-10
MX2013003735A (es) 2013-07-29
HRP20161637T1 (hr) 2017-03-10

Similar Documents

Publication Publication Date Title
ES2606545T3 (es) Método de almacenar una vacuna que contiene un adyuvante de aluminio
ES2695158T3 (es) Sistema de envasado para fármacos sensibles al oxígeno
DOP2017000190A (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas
GB2467904B (en) Drug container and delivery mechanism
ES2552921T3 (es) Un tapón de caucho para un contenedor de vial médico
AR064540A1 (es) Dispositivo de inhalacion para medicamentos en forma de polvo
JP2010194332A5 (es)
AR082910A1 (es) Inhalador de dosis medida y metodo para usar el mismo
ECSP13012704A (es) Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
Garg et al. A comparative evaluation of effect on water sorption and solubility of a temporary soft denture liner material when stored either in distilled water, 5.25% sodium hypochlorite or artificial saliva: An: in vitro: study
US11207477B2 (en) Formulation and aerosol canisters, inhalers, and the like containing the formulation
West et al. Nocardia spinal epidural abscess: 14-year follow-up
CN218751955U (zh) 一种疫苗运输用防震避光包装装置
Nishimura et al. Cognitive decline due to ectopic primary hyperparathyroidism
ES2659793T3 (es) Utilización de un material que comprende una matriz sólida a base de un polímero de silicona y cargas inorgánicas como material de un material neutrófago
Porto et al. Evaluation of short-and medium-term sorption and solubility of methacrylate or silorane-based composite resins in artificial saliva
CN104165268B (zh) 永久性气瓶充装限位架
Mok et al. A recent 10-year clinical and epidemiological study on zoster under 20 years old
Wang et al. Establishment of an in-vitro root canal-apical complex model
Quijano et al. Epstein-Barr virus presence in Colombian Hodgkin lymphoma cases and its relation to treatment response.
Seaux et al. M9: Current mumps outbreak in Belgium: is laboratory confirmation by IgM useful?
Cuenca Jurisprudència ambiental Castella La Manxa (Segon semestre 2011)
Rotimi et al. Does the Laryngeal Mask Airway Attenuate the Rise in Plasma Catecholamine Associated with the Laryngopressor Response?
Oda Bromide intoxication: case report
Van Parys et al. How and why Salmonella Typhimurium circumvents seroconversion in pigs